Hikma launches argatroban injection

London, 13 December 2012 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (“Hikma”), the fast growing multinational pharmaceutical group, today announces the US launch of argatroban injection, following the approval of its New Drug Application (NDA) by the US Food and Drug Administration (FDA) earlier this year.

Press Release Product 13 December 2012

Hikma’s argatroban is indicated for the prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in adult patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).

Said Darwazah, CEO of Hikma, said, “Hikma is pleased to be bringing argatroban injection to market. Argatroban will expand our injectables product line and help to differentiate our product portfolio in the US."

According to IMS Health, sales of argatroban injection were approximately $105 million for the 12 months ending October 2012. Hikma is marketing argatroban injection in 100mg/ml vials. Hikma’s argatroban was developed through Hikma’s partnership with the speciality pharmaceutical company, Exela Pharma Sciences, LLC.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.